(Q57076282)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22830373%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

title

British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22830373%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22830373%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Pat Tookey

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22830373%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

P Clayden

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22830373%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

J Dhar

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22830373%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

K Gandhi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22830373%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

K Harding

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22830373%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

P Hay

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22830373%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

J Kennedy

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22830373%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

N Low-Beer

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22830373%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

H Lyall

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22830373%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

A Palfreeman

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22830373%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

S Welch

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22830373%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

E Wilkins

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22830373%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

A de Ruiter

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22830373%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

G P Taylor

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22830373%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

publication date

1 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22830373%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22830373%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

13 Suppl 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22830373%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

87-157

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22830373%20AND%20SRC:MED&resulttype=core&format=json

Vertical transmission rates for HIV in the British Isles: estimates based on surveillance data.

8 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000???2006

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Pregnancy outcomes in adolescents in the UK and Ireland growing up with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Uptake of antenatal HIV testing in the United Kingdom: 2000-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Demographic, clinical and social factors associated with human immunodeficiency virus infection and other sexually transmitted diseases in a cohort of women from the United Kingdom and Ireland. MRC Collaborative Study of women with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Inequalities in rates of gonorrhoea and chlamydia between black ethnic groups in south east London: cross sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. Bangkok Collaborative Perinatal HIV Transmission Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Determinants of HIV-1 shedding in the genital tract of women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Differences in HIV-1 pol Sequences From Female Genital Tract and Blood During Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

The causal role for genital ulcer disease as a risk factor for transmission of human immunodeficiency virus. An application of the Bradford Hill criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Côte d'Ivoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Correlation between human immunodeficiency virus type 1 RNA levels in the female genital tract and immune activation associated with ulceration of the cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Activation of human immunodeficiency virus type 1 expression by Gardnerella vaginalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Induction of human immunodeficiency virus type 1 expression by anaerobes associated with bacterial vaginosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Treatment of cervicitis is associated with decreased cervical shedding of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Maternal Herpes simplex virus type 2 infection, syphilis and risk of intra-partum transmission of HIV-1: results of a case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Maternal herpes simplex virus type 2 coinfection increases the risk of perinatal HIV transmission: possibility to further decrease transmission?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Genital HSV detection among HIV-1-infected pregnant women in labor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Intrauterine infection and preterm delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The Women and Infants Transmission Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

The Ariel Project: A prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

A phase III clinical trial of antibiotics to reduce chorioamnionitis-related perinatal HIV-1 transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Association between Bacterial Vaginosis and Preterm Delivery of a Low-Birth-Weight Infant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Antibiotics for treating bacterial vaginosis in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Do screening-preventative interventions in asymptomatic pregnancies reduce the risk of preterm delivery--a critical appraisal of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Illness during pregnancy and bacterial vaginosis are associated with in-utero HIV-1 transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Antibiotics for treating bacterial vaginosis in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

British HIV Association, BASHH and FSRH guidelines for the management of the sexual and reproductive health of people living with HIV infection 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Myelomeningocele in a child with intrauterine exposure to efavirenz.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Myelomeningocele in an infant with intrauterine exposure to efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI perinatal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Use of zidovudine-sparing HAART in pregnant HIV-infected women in Europe: 2000-2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Antiretroviral regimens in pregnancy and breast-feeding in Botswana

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Experience of nevirapine use in a London cohort of HIV-infected pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Safety of nevirapine in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Safety and efficacy of saquinavir soft-gelatin capsules + zidovudine + optional lamivudine in pregnancy and prevention of vertical HIV transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Combination antiretroviral therapy and duration of pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Antiretroviral therapy during pregnancy and the risk of an adverse outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Lopinavir/ritonavir in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type 1-infected women and newborn infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Impact of pregnancy on abacavir pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus--infected pregnant women and their neonates: an AIDS clinical trials group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Lopinavir protein binding in HIV-1-infected pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Lopinavir tablet pharmacokinetics with an increased dose during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Atazanavir pharmacokinetics with and without tenofovir during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Placental transfer of enfuvirtide in the ex vivo human placenta perfusion model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Management of pregnancy in an HIV elite controller

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Postpartum changes in plasma viral load and CD4 percentage among HIV-infected women from Latin American and Caribbean countries: the NISDI Perinatal Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Effect of postpartum HIV treatment discontinuation on long-term maternal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Treatment interruption after pregnancy: effects on disease progression and laboratory findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

CD4+ count-guided interruption of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Effect of early versus deferred antiretroviral therapy for HIV on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Pregnant women with HIV infection can expect healthy survival: three-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Prevention of HIV-1 infection with early antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Côte d'Ivoire: the ANRS 1236 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

HIV/hepatitis B virus co-infection: current challenges and new strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Elective caesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus--a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Hepatitis B or hepatitis C coinfection in HIV-infected pregnant women in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Impact of maternal HIV coinfection on the vertical transmission of hepatitis C virus: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Influence of maternal human immunodeficiency virus (HIV) co-infection on vertical transmission of hepatitis C virus (HCV): a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. European Paediatric Hepatitis C Virus Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Increased vertical transmission of human immunodeficiency virus from hepatitis C virus-coinfected mothers. Women and Infants Transmission Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

A prospective study on mother-to-infant transmission of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Human immunodeficiency virus-hepatitis C virus co-infection in pregnant women and perinatal transmission to infants in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

A significant sex--but not elective cesarean section--effect on mother-to-child transmission of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Vertically acquired paediatric coinfection with HIV and hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

When does mother to child transmission of hepatitis C virus occur?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Hepatitis B vaccination during pregnancy for preventing infant infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Efficacy of an accelerated hepatitis B vaccination program during pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Effect of cesarean section on the risk of perinatal transmission of hepatitis C virus from HCV-RNA+/HIV- mothers: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

HCV/HIV co-infection, HCV viral load and mode of delivery: risk factors for mother-to-child transmission of hepatitis C virus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Maternal serum α-fetoprotein and human chorionic gonadotropin levels in women with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Multiple-marker screening in human immunodeficiency virus–positive pregnant women: screen positivity rates with the triple and quad screens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

The impact of protease inhibitors on maternal serum screening analyte levels in pregnant women who are HIV positive

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts. SEROGEST French Pediatric HIV Infection Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Amniocentesis and mother-to-child human immunodeficiency virus transmission in the Agence Nationale de Recherches sur le SIDA et les Hépatites Virales French Perinatal Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Chronic viral infections and invasive procedures: risk of vertical transmission and current recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Management of breech presentation in areas with high prevalence of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1--a meta-analysis of 15 prospective cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Trends in management and outcome of pregnancies in HIV-infected women in the UK and Ireland, 1990-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Postoperative infectious morbidities of cesarean delivery in human immunodeficiency virus-infected women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Experience of delivering women with HIV in an inner city London hospital 1994-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

The relationship of the duration of ruptured membranes to vertical transmission of human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Acute and chronic chorioamnionitis and the risk of perinatal human immunodeficiency virus-1 transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Antibiotics for preterm rupture of membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Codon 215 mutations in human immunodeficiency virus-infected pregnant women. Swiss Collaborative 'HIV and Pregnancy' Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

HIV-1 genotypic zidovudine drug resistance and the risk of maternal--infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Use of neonatal post-exposure prophylaxis for prevention of mother-to-child HIV transmission in the UK and Ireland, 2001-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Abacavir pharmacokinetics in human immunodeficiency virus-infected children ranging in age from 1 month to 16 years: a population analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Nevirapine concentrations in newborns receiving an extended prophylactic regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Lopinavir/ritonavir population pharmacokinetics in neonates and infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Association of Prenatal and Postnatal Exposure to Lopinavir-Ritonavir and Adrenal Dysfunction Among Uninfected Infants of HIV-Infected Mothers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Pharmacokinetics and tolerance of zidovudine in preterm infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Increased incidence of necrotizing enterocolitis in premature infants born to HIV-positive mothers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Evaluation of 4 weeks' neonatal antiretroviral prophylaxis as a component of a prevention of mother-to-child transmission program in a resource-rich setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Risk of human immunodeficiency virus type 1 transmission through breastfeeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Effect of breastfeeding on mortality among HIV-1 infected women: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

British HIV Association and Children's HIV Association position statement on infant feeding in the UK 2011

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Breastfeeding, mother-to-child HIV transmission, and mortality among infants born to HIV-Infected women on highly active antiretroviral therapy in rural Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Increased infant human immunodeficiency virus-type one free survival at one year of age in sub-saharan Africa with maternal use of highly active antiretroviral therapy during breast-feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Breastfeeding with maternal antiretroviral therapy or formula feeding to prevent HIV postnatal mother-to-child transmission in Rwanda

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Maternal or infant antiretroviral drugs to reduce HIV-1 transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Early weaning increases diarrhea morbidity and mortality among uninfected children born to HIV-infected mothers in Zambia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Frequency of gastroenteritis and gastroenteritis-associated mortality with early weaning in HIV-1-uninfected children born to HIV-infected women in Malawi

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

CD4+ T cells spontaneously producing human immunodeficiency virus type I in breast milk from women with or without antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Method of feeding and transmission of HIV-1 from mothers to children by 15 months of age: prospective cohort study from Durban, South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Performance of HIV-1 DNA or HIV-1 RNA tests for early diagnosis of perinatal HIV-1 infection during anti-retroviral prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

HIV prevalence, risk, and partner serodiscordance among pregnant women in Bangkok. Bangkok Collaborative Perinatal HIV Transmission Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Women living with HIV: disclosure, violence, and social support

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Sexual ethics. Disclosure of HIV-positive status to partners.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Factors affecting HIV concordancy in married couples in four African cities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure (2011).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Dispersal of HIV positive asylum seekers: national survey of UK healthcare providers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Alternative dosage of zidovudine in infants exposed to maternal human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

High levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Very high concentrations of active intracellular phosphorylated emtricitabine in neonates (ANRS 12109 trial, step 2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Going from evidence to recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Progression of HIV Disease Among Women Following Delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Mitomycin C Potentiates Ultraviolet-related Cytotoxicity in Corneal Fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

Prevention of vertical HIV transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2012.01030.X

10.1111/J.1468-1293.2012.01030.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22830373%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference